The key to overcoming addictions and psychiatric disorders lives deep inside the netherworld of our brains and the circuitry that causes us to feel good.
Just like space, this region of the brain needs more exploration.
The oldest and most known reward pathway is the mesolimbic dopamine system, which is composed of neurons projecting from the ventral tegmental area (VTA) to the nucleus accumbens -- a key structure in mediating emotional and motivation processing,
Dopamine is a neurotransmitter that is released when the brain is expecting reward. A spike in dopamine could come be from eating pizza, dancing, shopping, and sex. But it can also come from drugs and lead to substance abuse.
In search of ways of treating addiction and psychiatric illness, researchers are looking for pathways beyond dopamine that could play a key role in rewards and reinforcement.
In a paper published in Nature Neuroscience, researchers pushed the science forward on our reward pathways and found there is another pathway beyond dopamine. The Lab is expanding knowledge of the inner workings of the brain and identifying treatments for psychiatric diseases.
“This study opens new avenues to understanding reward circuitry that might be altered in abuse of nicotine, opiates, or other drugs as well as neuropsychiatric diseases that affect reward processing including depression,” said corresponding author. The Lab is expanding knowledge of the inner workings of the brain and identifying treatments for psychiatric diseases.
In this study, researchers found that approximately 30% of cells in the VTA are GABA neurons. VTA GABA neurons have increasingly been recognized as players in reward and aversion, as well as potential targets for the treatment of addiction, depression, and other stress-linked disorders.
Neurons are the fundamental units of the brain and nervous system, the cells responsible for receiving sensory input from the external world, for sending motor commands to our muscles, and for transforming and relaying the electrical signals at every step in between.
“What we found are unique GABAergic cells that project broadly to the nucleus accumbens, but projections only to a specific portion contribute to reward reinforcement,” said co-lead author.
In both male and female mice, researchers showed that long-range GABA neurons from the VTA to the ventral, but not the dorsal, nucleus accumben shell are engaged in reward and reinforcement behavior. They showed that this GABAergic projection inhibit cholinergic interneurons -- key players in reward-related learning.
As the researchers wrote: These findings “further our understanding of neuronal circuits that are directly implicated in neuropsychiatric conditions such as depression and addiction.”
Co-lead author likened the findings to building with Legos and figuring out how one piece connects to another .Each piece of the puzzle can take multiple years.
The author said the findings are allowing scientists to understand subregions of the brain and to visualize how specific neuromodulators are released during reward processing.
In science terms, the researchers are able to highlight heterogeneity in the brain -- or differences in the brain.
“It’s really important that we don’t think of structures in the brain as monolithic,” said the author. “There’s lots of little nuance in brain. How plastic it is. How it’s wired. This finding is showing one way how differences can play out.”
https://newsroom.uw.edu/postscript/beyond-dopamine-new-reward-circuitry-discovered
https://www.nature.com/articles/s41593-021-00898-2
New reward circuitry discovered!
- 1,158 views
- Added
Edited
Latest News
TB blood test which could d…
By newseditor
Posted 27 Mar
Propionate supplementation…
By newseditor
Posted 27 Mar
Role of human Kallistatin i…
By newseditor
Posted 26 Mar
Addressing both flu and COV…
By newseditor
Posted 26 Mar
How the brain senses body p…
By newseditor
Posted 26 Mar
Other Top Stories
Protecting genetic privacy in research
Read more
How melatonin promotes sleep
Read more
Neuronal uptake of amyloid beta in Alzheimer's disease
Read more
A novel monoclonal antibody therapy in a phase 2 trail cuts LDL cho…
Read more
Pituitary peptide modulates alcohol dependence and anxiety-like beh…
Read more
Protocols
All-optical presynaptic pla…
By newseditor
Posted 23 Mar
Epigenomic tomography for p…
By newseditor
Posted 20 Mar
A mouse DRG genetic toolkit…
By newseditor
Posted 17 Mar
An optogenetic method for t…
By newseditor
Posted 13 Mar
Profiling native pulmonary…
By newseditor
Posted 08 Mar
Publications
Integrated plasma proteomic…
By newseditor
Posted 27 Mar
APP antisense oligonucleoti…
By newseditor
Posted 27 Mar
Targeting Erbin-mitochondri…
By newseditor
Posted 27 Mar
Regulation of Zbp1 by miR-9…
By newseditor
Posted 27 Mar
Pain-free oral delivery of…
By newseditor
Posted 27 Mar
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar